FRACTALKINE: PATHOGENIC ROLE AND DIAGNOSTIC CAPABILITIES

FRACTALKINE: PATHOGENIC ROLE AND DIAGNOSTIC CAPABILITIES

The review presents modern data on the pathogenic role of CC chemokine is CX3CL1 or fractalkine in the cascade of immune responses in various diseases. The material presented sistematizirovat the most significant results of the work of clinical diagnostic value fractalkine in pathological conditions...

Full description

Bibliographic Details
Main Authors:	O. A. MESNYANKINA, E. Yu. YANCHEVSKAYA, M. BEN
Format:	Article
Language:	Russian
Published:	Ministry of Healthcare of the Russian Federation. “Kuban State Medical University” 2017-06-01
Series:	Кубанский научный медицинский вестник
Subjects:	chemokine-cx3cl1 fractalkine atopic dermatitis
Online Access:	https://ksma.elpub.ru/jour/article/view/723

Similar Items

CLINICAL AND DIAGNOSTIC VALUE OF THE DETERMINANTION OF FRACTALKINE IN ATOPIC DERMATITIS OF CHILDREN
by: M M Ben, et al.
Published: (2018-12-01)

Ligand-competent fractalkine receptor is expressed on exosomes
by: Eun Jeong Park, et al.
Published: (2021-07-01)

Neuroinflammation and fractalkine signaling in Alzheimer’s disease
by: Dylan J. Finneran, et al.
Published: (2019-02-01)

The role of сhemokine CX3CL1/Fractalkine in chronic viral hepatitis B
by: Natalia A. Arsentieva, et al.
Published: (2024-07-01)

Fractalkine Is Linked to the Necrosome Pathway in Acute Pulmonary Inflammation
by: Kristian-Christos Ngamsri, et al.
Published: (2021-03-01)

The role of the CX3CL1/CX3CR1 axis as potential inflammatory biomarkers in subjects with periodontitis and rheumatoid arthritis: A systematic review
by: Mario A. Alarcón‐Sánchez, et al.
Published: (2024-02-01)

CX3CL1/Fractalkine: A Potential Biomarker for Liver Fibrosis in Chronic HBV Infection
by: Natalia A. Arsentieva, et al.
Published: (2024-09-01)

The chemokine fractalkine (CX3CL1) attenuates H2O2-induced demyelination in cerebellar slices
by: Sinead A. O’Sullivan, et al.
Published: (2017-08-01)

CLINICAL AND DIAGNOSTIC VALUE OF DETERMINATION OF NEOPTERIN IN ATOPIC DERMATITIS IN CHILDREN
by: M. M. BEN, et al.
Published: (2018-07-01)

Fractalkine (CX3CL1) and Its Receptor CX3CR1: A Promising Therapeutic Target in Chronic Kidney Disease?
by: Sarah Cormican, et al.
Published: (2021-06-01)

An overview of the role of chemokine CX3CL1 (Fractalkine) and CX3C chemokine receptor 1 in systemic sclerosis
by: Fatemehsadat Pezeshkian, et al.
Published: (2024-10-01)

CX3CL1 release during immunogenic apoptosis is associated with enhanced anti-tumour immunity
by: Faye Naessens, et al.
Published: (2024-07-01)

Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases
by: Tanaka Y, et al.
Published: (2020-11-01)

Anti-CX3CL1 (fractalkine) monoclonal antibody attenuates lung and skin fibrosis in sclerodermatous graft-versus-host disease mouse model
by: Takumi Hasegawa, et al.
Published: (2024-05-01)

Role of fractalkine–CX3CR1 pathway in seizure-induced microglial activation, neurodegeneration, and neuroblast production in the adult rat brain
by: Idrish Ali, et al.
Published: (2015-02-01)

The Fractalkine‐CX3CR1 Axis Regulates Non‐inflammatory Osteoclastogenesis by Enhancing Precursor Cell Survival
by: Yoshikazu Kuboi, et al.
Published: (2022-10-01)

Reduced brain fractalkine-CX3CR1 signaling is involved in the impaired cognition of streptozotocin-treated mice
by: Namiko Kawamura, et al.
Published: (2020-12-01)

The role of microglia in adult hippocampus neurogenesis
by: Carmelina eGemma, et al.
Published: (2013-11-01)

Fractalkine/CX<sub>3</sub>CR1 in Dilated Cardiomyopathy: A Potential Future Target for Immunomodulatory Therapy?
by: Visvesh Jeyalan, et al.
Published: (2023-09-01)

Pathophysiological impact of CXC and CX3CL1 chemokines in preeclampsia and gestational diabetes mellitus
by: Amin Ullah, et al.
Published: (2023-10-01)

Fractalkine modulates pulmonary angiogenesis and tube formation by modulating CX3CR1 and growth factors in PVECs
by: Liao Jun, et al.
Published: (2023-12-01)

Effects of long-term exercise training on adipose tissue expression of fractalkine and MCP-1 in patients with type 2 diabetes and stable coronary artery disease: a substudy of a randomized controlled trial
by: Njerve IU, et al.
Published: (2016-03-01)

The Impact of Uremic Toxicity Induced Inflammatory Response on the Cardiovascular Burden in Chronic Kidney Disease
by: Ligia Maria Claro, et al.
Published: (2018-09-01)

MicroRNA-424 regulates the expression of CX3CL1 (fractalkine) in human microvascular endothelial cells during Rickettsia rickettsii infection
by: Abha Sahni, et al.
Published: (2021-03-01)

Neuron–glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage
by: Graham K. Sheridan, et al.
Published: (2013-01-01)

Identifying a Novel Role for Fractalkine (CX3CL1) in Memory CD8+ T Cell Accumulation in the Omentum of Obesity-Associated Cancer Patients
by: Melissa J. Conroy, et al.
Published: (2018-08-01)

Fractalkine/CX3CR1 axis is critical for neuroprotection induced by hypoxic postconditioning against cerebral ischemic injury
by: Lixuan Zhan, et al.
Published: (2024-09-01)

Triptolide alleviates cerebral ischemia/reperfusion injury via regulating the Fractalkine/CX3CR1 signaling pathway
by: Jiajun Zhou, et al.
Published: (2024-06-01)

Fractalkine Modulates Microglia Metabolism in Brain Ischemia
by: Clotilde Lauro, et al.
Published: (2019-09-01)

Innate Immunity to Spiral Ganglion Neuron Loss: A Neuroprotective Role of Fractalkine Signaling in Injured Cochlea
by: Andrew Rigel Stothert, et al.
Published: (2021-08-01)

Age-dependent changes on fractalkine forms and their contribution to neurodegenerative diseases
by: Jaime Eugenín, et al.
Published: (2023-09-01)

Tenophages: a novel macrophage-like tendon cell population expressing CX3CL1 and CX3CR1
by: Christine Lehner, et al.
Published: (2019-12-01)

Implications of fractalkine on glial function, ablation and glial proteins/receptors/markers—understanding its therapeutic usefulness in neurological settings: a narrative review
by: Deepraj Paul, et al.
Published: (2022-12-01)

Examination of the Fractalkine and Fractalkine Receptor Expression in Fallopian Adenocarcinoma Reveals Differences When Compared to Ovarian Carcinoma
by: Hilal Gurler, et al.
Published: (2015-12-01)

Heterozygous CX3CR1 Deficiency in Microglia Restores Neuronal β-Amyloid Clearance Pathways and Slows Progression of Alzheimer's Like-Disease in PS1-APP Mice
by: Suzanne E. Hickman, et al.
Published: (2019-12-01)

A calpain inhibitor protects against fractalkine production in lipopolysaccharide-treated endothelial cells
by: Jaewoong Jang, et al.
Published: (2017-09-01)

Analysis of the links between endothelium-dependent vasodilation indicators and the levels of high-sensitivity C-reactive protein and fractalkine/CX3CL1 in patients with acute coronary syndrome
by: E. A. Polunina, et al.
Published: (2020-06-01)

Chemokine CX3CL1 has potential anti-fibrosis effect in mouse liver fibrosis
by: CHENG Qi, LI Ning, YU Kangkang, SHI Guangfeng
Published: (2023-12-01)

Computational Insights into the Interaction of the Conserved Cysteine-Noose Domain of the Human Respiratory Syncytial Virus G Protein with the Canonical Fractalkine Binding site of Transmembrane Receptor CX3CR1 Isoforms
by: João Victor Piloto, et al.
Published: (2024-04-01)

Treatment with an Anti-CX3CL1 Antibody Suppresses M1 Macrophage Infiltration in Interstitial Lung Disease in SKG Mice
by: Satoshi Mizutani, et al.
Published: (2021-05-01)